Agile or Waterfall? Why Pharma Projects Must Align the Method With the Question

The question of whether a pharma project should be run agile or according to the waterfall model is often debated as a matter of method or culture. That falls short. In an environment shaped by regulatory requirements, extensive documentation, cross-functional teams and patient safety, it is not the project manager's preference that decides, but the regulatory character of the undertaking. The method is a dependent variable, not the first decision point.

When Waterfall Is the Superior Choice

The waterfall model is a linear, phase-based approach: requirements, design, development, testing and implementation are completed one after another. In the pharmaceutical industry it is the preferred approach wherever high regulatory control, end-to-end documentation and validation are paramount:

• Implementation of validated IT systems such as LIMS, DMS, QMS, RIM or ERP.
• Qualification of equipment and validation of production lines.
• Projects with a fixed scope and clearly defined requirements.
• Preparation for authority inspections by FDA, EMA or WHO, with validation to GAMP 5.

Its strength is at the same time its limit: the clear documentation chain and the structured sequence fit the audit logic exactly, yet flexibility is low, late changes are expensive, and a usable result only becomes visible late.

Where Agile Works in Pharma

Agile delivers in short iterations, with frequent feedback and continuous involvement of those concerned. In a regulated environment, it plays to its strengths above all away from the validation-critical core:

• Digital initiatives such as CRM, BI or BPM systems.
• Internal IT development and process automation.
• Pilot projects and undertakings with evolving requirements.
• Digitalisation projects with a quick contribution to value.

The advantage is early benefit, easily integrated feedback and high transparency about progress. The limitation is just as clear: agile presupposes experienced, mature teams, is not readily compatible with GxP documentation and calls for additional controls in order to meet regulatory requirements.

The Decisive Difference Lies in the Concept of Error

The deeper reason for this limit lies in the origin of agile. The method comes from software development, where an error usually means a bug or a missing function, and iteration, testing and learning from mistakes follow logically. In drug development, an error can concern patient safety. For this reason, the agile mindset cannot be transferred unchanged to clinical trials, drug development or manufacturing validation: there it must be supplemented by strict controls and compliance evidence, otherwise the approach loses precisely the safeguards that the regulated environment demands.

The Hybrid Approach Wins Most of the Time

In practice, many pharma projects are therefore run in a hybrid manner. Documentation, validation and regulatory traceability follow the waterfall logic, while task management, team collaboration and feedback loops are organised in an agile way. This preserves reviewability and audit readiness, while the project delivers value iteratively and stakeholders are more closely involved. Which mix is right follows from a few factors: type and scope of the project, regulatory requirements, structure and maturity of the team, degree of customer involvement and clarity of the requirements.

How Entourage Supports You

We do not start with the method, but with the question: which part of the undertaking is validation- and documentation-driven, and which benefits from iteration? From this separation we derive the appropriate approach, anchor the GxP-relevant evidence to GAMP 5 and Annex 11 in the structured strand, and organise the development- and digitalisation-related parts in an agile way. This creates a project structure that does not play control and speed off against each other, but gives each work strand the logic that fits it.